74 Chapter 4 References 1. Karakike E, Giamarellos-Bourboulis EJ. Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis. Front Immunol. 2019;10:55. 2. Lachmann G, Knaak C, Vorderwülbecke G, et al. Hyperferritinemia in Critically Ill Patients. Crit Care Med. 2020; 48(4):459–465. 3. Piagnerelli M, Cotton F, Herpain A, et al. Time course of iron metabolism in critically ill patients. Acta Clin Belg. 2013; 68(1):22–27. 4. Brands X, Vries FMC de, Uhel F, et al. Plasma Ferritin as Marker of Macrophage ActivationLike Syndrome in Critically Ill Patients With Community-Acquired Pneumonia. Crit Care Med. 2021; 49(11):1901–1911. 5. Senjo H, Higuchi T, Okada S, Takahashi O. Hyperferritinemia: causes and significance in a general hospital. Hematology. 2018; 23(10):817–822. 6. Cullis JO, Fitzsimons EJ, Griffiths WJ, Tsochatzis E, Thomas DW. Investigation and management of a raised serum ferritin. Br J Haematol. 2018; 181(3):331–340. 7. Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol. 2017; 29(9):401– 409. 8. Kell DB, Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics. 2014; 6(4):748–773. 9. Schaffner M, Rosenstein L, Ballas Z, Suneja M. Significance of Hyperferritinemia in Hospitalized Adults. Am J Med Sci. 2017; 354(2):152–158. 10. Kyriazopoulou E, Leventogiannis K, Norrby-Teglund A, et al. Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. BMC Med. 2017; 15(1):172. 11. Angus DC, Poll T van der. Severe sepsis and septic shock. N Engl J Med. 2013; 369(9):840–851. 12. Troeger C, Blacker B, Khalil IA, et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018; 18(11):1191–1210. 13. Kyriazopoulou E, Poulakou G, Milionis H, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021; 27(10):1752–1760. 14. Berk IAH van den, Kanglie MMNP, Engelen TSR van, et al. OPTimal IMAging strategy in patients suspected of non-traumatic pulmonary disease at the emergency department: chest X-ray or ultra-low-dose CT (OPTIMACT)—a randomised controlled trial chest X-ray or ultralow-dose CT at the ED: design and rationale. Diagnostic Progn Res. 2018; 2:20. 15. Kanglie MMNP, Bipat S, Berk IAH van den, et al. OPTimal IMAging strategy in patients suspected of non-traumatic pulmonary disease at the emergency department: chest X-ray or ultra-low-dose chest CT (OPTIMACT) trial-statistical analysis plan. Trials. 2020; 21(1):407. 16. Brands X, Haak BW, Klarenbeek AM, et al. Concurrent Immune Suppression and Hyperinflammation in Patients With Community-Acquired Pneumonia. Front Immunol. 2020; 11:796. 17. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336(4):243–250. 18. Woude SW van der, Doormaal FF van, Hutten BA, J Nellen F, Holleman F. Classifying sepsis patients in the emergency department using SIRS, qSOFA or MEWS. Neth J Med. 2018; 76(4):158–166. 19. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801–810.
RkJQdWJsaXNoZXIy MTk4NDMw